The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

NCT04876651 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped Telix is conducting a separate Phase 3 clinical trial - ProstACT Global NCT06520345- to expedite the development and approval process under an IND. Consequently, this necessitates the closure of the current 177Lu-TLX591-002 Phase 3 trial.

Conditions

Interventions

Sponsor

Telix Pharmaceuticals (Innovations) Pty Ltd